These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 3882353)
1. Response of a 'susceptible' Escherichia coli to metronidazole therapy: an investigation using experimental subcutaneous abscesses. Reznikov M; Hakendorf PH; Matthews DB Chemotherapy; 1985; 31(1):50-4. PubMed ID: 3882353 [TBL] [Abstract][Full Text] [Related]
2. Effect of metronidazole on Escherichia coli in the presence of Bacteroides fragilis: an investigation in mice. Reznikov M; McDonald PJ Chemotherapy; 1983; 29(3):225-9. PubMed ID: 6347547 [TBL] [Abstract][Full Text] [Related]
3. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli. Brook I; Ledney GD J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005 [TBL] [Abstract][Full Text] [Related]
4. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes. Brook I J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934 [TBL] [Abstract][Full Text] [Related]
5. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities. Brook I Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727 [TBL] [Abstract][Full Text] [Related]
6. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses. Wells CL; Arland LA; Simmons RL; Rotstein OD J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172 [TBL] [Abstract][Full Text] [Related]
7. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis. Brook I Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944 [TBL] [Abstract][Full Text] [Related]
8. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Fu KP; Vince T; Bloom R; Gregory FJ; Hung PP Drugs Exp Clin Res; 1987; 13(8):493-6. PubMed ID: 3322752 [TBL] [Abstract][Full Text] [Related]
11. Quantification of the effect of anti-anaerobic drugs in experimental Bacteroides fragilis infection in mice. Dijkmans BA; Mattie H; Hermans J; van Furth R J Antimicrob Chemother; 1984 Jan; 13(1):79-86. PubMed ID: 6365877 [TBL] [Abstract][Full Text] [Related]
12. Intravenous metronidazole therapy for Bacteroides fragilis meningitis. Bryan CS; Huffman LJ; Del Bene VE; Sanders CV; Scalcini MC South Med J; 1979 Apr; 72(4):494-7. PubMed ID: 373128 [TBL] [Abstract][Full Text] [Related]
13. Metronidazole and spiramycin in abscesses caused by Bacteroides spp. and Staphylococcus aureus in mice. Brook I J Antimicrob Chemother; 1987 Nov; 20(5):713-8. PubMed ID: 3429373 [TBL] [Abstract][Full Text] [Related]
14. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752 [TBL] [Abstract][Full Text] [Related]
15. Antibiotic and clavulanic acid treatment of subcutaneous abscesses caused by Bacteroides fragilis alone or in combination with aerobic bacteria. Brook I; Coolbaugh JC; Walker RI J Infect Dis; 1983 Jul; 148(1):156-9. PubMed ID: 6350486 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of latamoxef (moxalactam) against both Bacteroides fragilis and Escherichia coli in an intraperitoneal abscess model. Harris RW; Moore WL; Arensman JB; Rissing JP J Antimicrob Chemother; 1984 Nov; 14(5):499-508. PubMed ID: 6392279 [TBL] [Abstract][Full Text] [Related]
17. Metronidazole and spiramycin therapy of mixed Bacteroides spp. and Neisseria gonorrhoeae infection in mice. Brook I Chemotherapy; 1989; 35(2):105-12. PubMed ID: 2503299 [TBL] [Abstract][Full Text] [Related]
18. Synergy between spiramycin and metronidazole in the treatment of polymicrobial infections. Brook I J Antimicrob Chemother; 1988 Jul; 22 Suppl B():77-85. PubMed ID: 3141350 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess. Fu KP; Lasinski ER; Zoganas HC; Kimble EF; Konopka EA J Antimicrob Chemother; 1984 Dec; 14(6):633-40. PubMed ID: 6520063 [TBL] [Abstract][Full Text] [Related]
20. Comparison of clindamycin, metronidazole, and penicillin for the treatment of experimental infections in mice caused by beta-lactamase-producing Bacteroides intermedius. Cockerill FR; Rosenblatt JE; Lee DT; Gay JD Diagn Microbiol Infect Dis; 1986 May; 5(1):25-30. PubMed ID: 3486740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]